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ABSTRACT
Introduction: Intrathecal drug delivery (ITDD) systems
are an option for the management of patients with
chronic non-cancer pain, cancer pain and spasticity.
Concerns over their invasiveness and high initial costs
have led National Health Service (NHS) England to
decommission ITDD for patients with chronic non-
cancer pain. However, the extent to which this decision
is in line with existing economic evidence is unclear.
To address this question, we will carry out a systematic
review to identify and evaluate the existing evidence on
the cost-effectiveness of ITDD for chronic non-cancer
pain.
Methods and analysis: A high-sensitivity search
strategy will be employed in Cochrane Library,
MEDLINE, EMBASE, Web of Science, NHS EED, DARE
and HTA. Database searches will be complemented by
additional searching techniques. Screening of the
results will be performed by 2 reviewers independently
using predetermined inclusion and exclusion criteria.
Full and partial economic evaluations will be included.
Data extraction will be carried out using a form created
for the purposes of this review. Quality assessment of
all included studies will be performed using
recommended checklists.
Ethics and dissemination: Ethical approval is not
required as primary data will not be collected. Findings
will be disseminated through peer-reviewed
publications and conference presentations.
PROSPERO registration number:
CRD42016035266.
INTRODUCTION
Definition of chronic pain
Chronic pain is often deﬁned according to
the duration of its symptoms, although the
time to heal or repair depends on the type
of the underlying injury or disease and is
extremely variable. For the purposes of con-
sistency, 3 months have been considered an
appropriate point to distinguish between
acute and chronic non-cancer pain, although
6 months is usually preferred for research
purposes.1 Chronic pain can also be charac-
terised as pain that persists past the time
point when an injury or disease is healed or
repaired has ended.1 Healing or repair does
not apply to several conditions that are
treated as chronic pain, such as rheumatoid
arthritis, osteoarthritis or spinal stenosis, and
therefore, the concept of chronic pain
should be understood as persistent pain that
is not responsive to speciﬁc treatments or to
typical pain relief methods including non-
narcotic analgesics.1
Prevalence of chronic pain
Estimates of the prevalence of chronic pain
vary across studies, mainly due to the
employed deﬁnition of chronic pain and the
populations studied. A survey conducted in
15 European countries and Israel deﬁned
chronic pain as pain lasting >6 months, with
pain being experienced several times during
the week prior to the survey, and the last
pain episode having an intensity of ﬁve or
more on a 1 (no pain) to 10 (worst pain
imaginable) numerical rating scale.2 Based
on this deﬁnition of chronic pain, Breivik
et al2 estimated the adult prevalence of
chronic pain in the UK to be 13%. The UK
Biobank study recruited 503 325 people aged
Strengths and limitations of this study
▸ First systematic review to investigate the cost-
effectiveness of intrathecal drug delivery (ITDD)
for chronic non-cancer pain.
▸ The review will consolidate the existing evidence
on the cost-effectiveness of ITDD for chronic
non-cancer pain.
▸ It may not be possible to pool estimates of
costs and cost-effectiveness.
▸ Data synthesis will follow good practice recom-
mendations in a narrative summary of health
economic studies.
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between 40 and 69 years in England, Scotland and
Wales.3 No speciﬁc characterisation of chronic pain was
used in this case; instead, the study relied on individuals
reporting their pain as acute or chronic. The study
found that the overall prevalence of chronic pain was
42.9% and increased with age from 39.6% for people
aged between 40 and 44 years to 45.7% for responders
with an age between 65 and 69 years.3 The Health
Survey for England characterised chronic pain as the
experience of pain or discomfort at all of the time or on
and off for >3 months.4 The prevalence of chronic pain
was found to be higher in women (37%) than in men
(31%), to increase with age from 14% of men and 18%
of women aged 16–34 years to 53% of men and 59% of
women aged 75 years and over, to be higher in those
living in the poorest households (40% of men and 44%
of women) than in the richest households (24% of men
and 30% of women) and to be higher in those living in
more deprived areas (36% of men and 42% of women)
than in those living in the least deprived areas (31% of
men and 34% of women).4 The prevalence of chronic
pain is higher than that of other common chronic con-
ditions such as diabetes mellitus, which has a consider-
ably lower prevalence of 7% among men and 4.9%
among women.5 Nevertheless, the Chief Medical
Ofﬁcer’s Annual Report indicated service provision for
pain management to be inadequate and existing services
not evenly distributed across the country.6
Impact on health and quality of life
Chronic pain represents a signiﬁcant health burden that
can lead to important reductions in health-related
quality of life (QoL). The National Pain Audit 2012
observed that the mean EuroQol index score in people
suffering with chronic pain was 0.4, which is lower than
that reported by people with progressive neurological
disorders such as Parkinson’s disease (0.432).7 It has
been reported that, of 291 conditions studied, 4 of the
12 top conditions to cause global disability are persistent
pain conditions including neck pain, migraine, arthritis
and low back pain.8 The latter was found to cause more
global disability than any other condition.8 Around 65%
of people with chronic pain report difﬁculty sleeping
and ∼16% of them feel that their pain is so bad that
sometimes they want to die.6
Economic burden of chronic pain
The economic burden of chronic pain is equally signiﬁ-
cant. It is estimated that back pain alone costs the UK
economy £12.3 billion per year with the cost of pain
from all causes being much higher.6 In the UK, people
with chronic pain report up to ﬁve times more general
practitioner (GP) appointments than the general popu-
lation, accounting for 4.6 million GP appointments per
year.4 9 Chronic pain sufferers are seven times more
likely to quit their job due to ill health than the general
population and chronic pain is the second most
common reason to claim incapacity beneﬁt.6 Pain was
found to have the greatest impact on ability to work as
measured by the Brief Pain Inventor; it prevented 40%
of people with chronic pain from working and led to
12% having to reduce their working hours.7
Interventions for chronic pain
A multitude of strategies are available for the manage-
ment of chronic non-cancer pain. Treatment strategies
for pain start with those with lowest risk and least inva-
siveness, and progress if the pain is refractory to the
treatment selected.10 For many patients, it can take
several years to identify treatments that can decrease
their pain and increase their QoL. Although treatments
may initially present some beneﬁts, in the long term,
those initial beneﬁts seem to subside. For example, oral
opioids, which are frequently used to alleviate postsur-
gery pain, lead to good short-term pain relief; however,
many chronic non-cancer pain patients discontinue
long-term therapy due to the need to increase the dose
required to obtain similar pain relief, or due to unbear-
able side-effects. In addition, there is only weak evidence
to support the effectiveness of oral opioids in patients
who are able to continue opioid therapy in the long
term.11
Spinal cord stimulation (SCS) and intrathecal drug
delivery (ITDD) have been seen as ‘last resort’ options,
which are typically made available to patients who have
experienced prolonged periods of pain, sometimes as
much as 40 years.12–14 The approach to start with those
strategies with lowest risk and least invasiveness can be
considered as reasonable from a clinical and economic
perspective because SCS and ITDD are costly, invasive
and carry additional treatment risks. However, it has
been observed that chronic pain may cause decrease in
brain grey matter, which can be normalised if pain is
adequately treated.15 16 Besides leading to a potential
brain grey matter loss, a longer duration of pain is also
associated with a decrease in perceived treatment efﬁ-
cacy.13 17 Therefore, it is important to identify effective
management options for chronic non-cancer pain at an
early stage. Expectations may inﬂuence a patient’s per-
ception of treatment efﬁcacy and it is important for the
patients to understand that there is no cure for chronic
pain, but there may be options that can help to decrease
their pain in a meaningful way, which can lead to
improvements in their QoL.
Intrathecal drug delivery
ITDD has been a recognised treatment for chronic non-
cancer pain since the ﬁrst opioid reservoir was
implanted in 1981.18 Since the administration of opioids
is performed directly to a site with opioid receptors, the
intrathecal dose required is much lower than that
needed when using the oral or epidural route.19 The
oral and epidural opioid doses are, respectively, 30020
and 2421 times higher than the same intrathecal dose.
Generally, the direct delivery to the intrathecal space
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and the lower dose required lead to a reduction of side-
effects and enable better analgesia.22
An ITDD system consists of a small battery-powered
pump implanted into the patients’ abdominal area,
which delivers medication directly to the intrathecal
space through a catheter. The daily dose to be adminis-
tered is programmed via an external device during reﬁll
appointments. The reﬁll procedure and necessary dose
adjustments are performed only by doctors or pain
nurses with experience in programming the ITDD
system.
Candidates for an ITDD undergo a multidisciplinary
assessment to evaluate suitability and a trial to assess the
patient’s response to the intrathecal drug. ITDD trial
methodologies are varied and none has proven super-
ior.23–25 An ITDD trialling algorithm has been devel-
oped suggesting alternative types of trialling strategies
based on the type of pain, drug to be administered and
time required to evaluate patient’s response among
other factors. For illustrative purposes, an ITDD trial
may be performed using an implanted catheter con-
nected to an external pump, in a single-blind placebo-
controlled fashion, with the intrathecal morphine and a
saline solution being administered in different days and
the patient’s response is recorded; patients who report
≥50% pain relief with intrathecal morphine will receive
an ITDD implant.
ITDD is used for the management of cancer and non-
cancer pain and spasticity.26 27 There are different levels
of evidence for the use of ITDD in these different condi-
tions. A randomised controlled trial (RCT) evaluating
the effectiveness of ITDD in cancer pain observed
improvements in pain control, QoL and signiﬁcantly less
drug toxicity with ITDD when compared with con-
ventional medical management.28 Although the current
evidence for the use of intrathecal baclofen for the man-
agement of spasticity is limited to case series, this treat-
ment is established in the UK.29 For chronic non-cancer
pain, the evidence on intrathecal delivery of opioids is
currently limited to case series and a small RCT suggest-
ing effectiveness of ITDD for pain relief in long-term
patients.30
National Health Service (NHS) England currently
commissions ITDD for the management of cancer
pain31 and spasticity32 but not for the pain of non-
cancer origin.33 Although the limitations of the effective-
ness data are undeniable, poor-quality economic evalua-
tions seem to have been used to inform the
commissioning decision for chronic non-cancer pain.
Aim and objectives
The overarching aim of this systematic review is to inves-
tigate the cost-effectiveness of ITDD systems using
opioids for the management of chronic non-cancer
pain.
Towards this aim, this work sets out to
▸ Search many sources to identify relevant evidence on
the cost-effectiveness of ITDD;
▸ Appraise the quality of the identiﬁed studies, and
highlight their strengths and limitations;
▸ Use evidence reported in the studies to determine
the cost-effectiveness of this treatment option;
▸ Discuss the potential policy implications of the ﬁnd-
ings, especially in relation to future policy reviews of
ITDD for chronic non-cancer pain;
▸ Highlight gaps in the existing evidence, and suggest
areas for further research.
METHODS AND ANALYSIS
This systematic review protocol follows the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses for Protocols (PRISMA-P) reporting guide-
lines.34 A PRISMA-P checklist can be found in online
supplementary additional ﬁle 1.
Search methods for the identification of studies
Systematic searches will be conducted to identify rele-
vant economic evaluations of ITDD for the management
of chronic non-cancer pain. The searches will be carried
out in the following sources:
▸ Databases: MEDLINE(R) In-Process and Other
Non-Indexed Citations and MEDLINE(R) (Ovid),
EMBASE (Ovid), Science Citation Index (Web of
Science), Conference Proceedings Citation Index
(Web of Science), Cochrane Library (Wiley) and the
National Health Service (NHS) Centre for Reviews
and Dissemination databases NHS EED, DARE and
HTA (all via Wiley).
▸ Grey literature databases: OpenGrey, GreyNet,
GreyLit.
Searches in the above bibliographic databases will be
complemented by
▸ Hand searching of reference lists of relevant studies.
▸ Consultation with experts in the ﬁeld for additional
information on unpublished and ongoing economic
evaluations.
Databases will be searched from their inception.
Economic studies ﬁlters designed by the NHS EED35
and SIGN36 to locate economic evaluation studies will
be also used. An example of the search strategy to be
used in searches in MEDLINE(R) (Ovid) is presented in
online supplementary additional ﬁle 2. No language
restriction will be applied in the searches. Literature
search results will be uploaded to and managed using
the EndNote V.X7.0.1 software.
Study selection
The selection criteria described in table 1 will be
applied to the citations identiﬁed from the literature
search. Two reviewers will screen titles and abstracts of
all retrieved citations independently. Full texts where
compliance with the selection criteria is unclear from
title and abstracts will be retrieved. Full papers for
studies deemed potentially relevant will be retrieved and
selection criteria will be applied. Disagreement will be
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resolved by discussion and consensus between the two
reviewers. A third reviewer will be involved if dissenting
opinions are observed and consensus is not reached.
The study selection process will be summarised in a
PRISMA ﬂow diagram.
Data extraction
Two reviewers will extract relevant information independ-
ently using an extraction form developed speciﬁcally for
the purposes of this study. A third reviewer will assess the
extracted data to ensure accuracy. Disagreements will be
resolved by discussion. Information will be extracted in
relation to the following factors: (1) general information
including study ID, author, year, funding source, country,
setting and study design; (2) recruitment details, sample
size, demographic characteristics (age, gender) and base-
line health data (diagnosis, comorbidities); (3) interven-
tions, effectiveness data and cost data; (4) type of
economic evaluation, perspective, time horizon and
measure of beneﬁt; (5) quality assessment; (6) results;
(7) analysis of uncertainty and (8) conclusions. The out-
comes for which data will be sought were selected taking
into account the data necessary to conduct an economic
evaluation.
Quality assessment
Quality assessment of all included studies will be per-
formed using the Evers checklist (all economic evalua-
tions)38 and the Philips checklist for model-based
economic studies39 as recommended in the Cochrane
Handbook for Systematic Reviews of Interventions.40
Two reviewers will independently assess the quality of
the included studies. Any discrepancies will be resolved
by discussion and consensus between the two reviewers
and if necessary consultation of a third reviewer. Quality
assessment of included studies will be presented in a
table format.
Data synthesis and reporting
The results section will be organised taking into consid-
eration the good practice recommendations in a narra-
tive summary of health economic studies from the
Cochrane Handbook for Systematic Reviews.41 The
recommendations advise detailed reports of methods
such as the study design; time horizon adopted; cur-
rency and price year; measures of beneﬁts used; assess-
ment of uncertainty; methodological quality and
limitations of all studies included in the review. The
actual results from the studies will be reported in a sep-
arate results subsection.
To facilitate the comparison of estimates reported in
different studies, monetary values reported in all the
identiﬁed studies will be converted to UK pounds ster-
ling (£) at 2015 price year. Conversion of cost estimates
will be performed using the CCEMG—EPPI-Centre Cost
Converter web-based tool V.1.4. The CCEMG—
EPPI-Centre Cost Converter tool takes into consideration
international exchange rates based on Purchasing Power
Parities and gross domestic product deﬂator values as
recommended in the economics evidence section of the
Cochrane Handbook for Systematic Reviews.41
ETHICS AND DISSEMINATION
Ethical approval is not required as primary data will not
be collected. Findings will be disseminated through peer-
reviewed publications and conference presentations.
DISCUSSION
Alongside clinical evidence, economic evaluations are
an important tool for policymakers. Taking into consid-
eration budget limitations, it is imperative that decisions
to recommend a treatment and make it available to
NHS patients are underpinned by robust evidence on its
clinical effectiveness and cost-effectiveness. In some occa-
sions, it is possible that important evidence with the
potential to inﬂuence decisions may not have been iden-
tiﬁed. Therefore, if there is uncertainty about the clinical
effectiveness or cost-effectiveness of a treatment, a system-
atic review should be commissioned prior to a decision.
Recently, NHS England has decommissioned the use of
ITDD for the management of chronic non-cancer pain.33
Poor-quality economic evaluations seem to have been
used to inform the commissioning decision. The authors
do not state that this review alone or the use of better
quality economic evaluations would lead to a change in
the decision, due to the limited evidence for effective-
ness. However, with better effectiveness data, the
Table 1 Inclusion criteria for the identification of relevant studies
Population Patients with chronic non-cancer pain lasting for at least 3 months prior to intervention
Intervention ITDD systems using opioids alone or in combination with other agents
Comparator Any comparator
Outcomes Effectiveness data (ie, patient-reported QoL, pain intensity, disability, patient satisfaction)
Direct and/or indirect costs to the healthcare system, patients and society
Items of resource use
Cost per unit of outcome (ie, cost-per-QALY, incremental cost-effectiveness ratio)
Study design Full and partial economic evaluations as defined by Drummond et al37
ITDD, intrathecal drug delivery; QALY, quality-adjusted life years; QoL, quality of life.
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assessment of poor economic evaluations (when better
evidence is available) could tip the decision towards non-
commissioning and as a consequence, access to patients
with non-cancer pain that could potentially beneﬁt from
ITDD would be denied.
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